Helminth Coinfection Does Not Affect Therapeutic Effect of a DNA Vaccine in Mice Harboring Tuberculosis by Frantz, Fabiani G. et al.
Helminth Coinfection Does Not Affect Therapeutic Effect
of a DNA Vaccine in Mice Harboring Tuberculosis
Fabiani G. Frantz
1,2, Roge ´rio S. Rosada
2, Camila Peres-Buzalaf
1,2, Franciele R. T. Perusso
1, Vanderlei
Rodrigues
2, Simone G. Ramos
2, Steven L. Kunkel
3,C e ´lio L. Silva
2,L u ´cia H. Faccioli
1*
1Faculdade de Cie ˆncias Farmace ˆuticas de Ribeira ˜o Preto, Universidade de Sa ˜o Paulo, Ribeira ˜o Preto, Sa ˜o Paulo, Brazil, 2Faculdade de Medicina de Ribeira ˜o Preto,
Universidade de Sa ˜o Paulo, Ribeira ˜o Preto, Sa ˜o Paulo, Brazil, 3Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, United States of
America
Abstract
Background: Helminthiasis and tuberculosis (TB) coincide geographically and there is much interest in exploring how
concurrent worm infections might alter immune responses against bacilli and might necessitate altered therapeutic
approaches. A DNA vaccine that codifies heat shock protein Hsp65 from M. leprae (DNAhsp65) has been used in therapy
during experimental tuberculosis. This study focused on the impact of the co-existence of worms and TB on the therapeutic
effects of DNAhsp65.
Methodology/Principal Findings: Mice were infected with Toxocara canis or with Schistosoma mansoni, followed by
coinfection with M. tuberculosis and treatment with DNAhsp65. While T. canis infection did not increase vulnerability to
pulmonary TB, S. mansoni enhanced susceptibility to TB as shown by higher numbers of bacteria in the lungs and spleen,
which was associated with an increase in Th2 and regulatory cytokines. However, in coinfected mice, the therapeutic effect
of DNAhsp65 was not abrogated, as indicated by colony forming units and analysis of histopathological changes. In vitro
studies indicated that Hsp65-specific IFN-c production was correlated with vaccine-induced protection in coinfected mice.
Moreover, in S. mansoni-coinfected mice, DNA treatment inhibited in vivo TGF-b and IL-10 production, which could be
associated with long-term protection.
Conclusions/Significance: We have demonstrated that the therapeutic effects of DNAhsp65 in experimental TB infection
are persistent in the presence of an unrelated Th2 immune response induced by helminth infections.
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Introduction
Helminth parasites cause significant morbidity worldwide, with
estimates indicating that approximately one-third of the almost
three billion people living on less than two US dollars per day in
developing regions of sub-Saharan Africa, Asia, and the Americas
are infected with one or more helminths [1,2]. Helminth infections
are potent Th2 response inducers in both humans and
experimental models, characterized by eosinophilia, high titers of
circulating IgE, enhanced Th2 cytokine profile [e.g., increased
secretion of interleukin 4 (IL-4) and IL-5], and regulatory (IL-10,
TGF-b) cytokines and reduced Th1 type cytokines [e.g., interferon
(IFN)-c] [3]. Toxocariasis is an underestimated soil-transmitted
helminthiasis that primarily affects people in developing countries
[4,5], including Brazil, where prevalence rates reach ,40% [6,7],
while Schistosomiasis causes 14000 deaths per year, with 200–300
million infected people and 10% at risk of infection worldwide,
according to the Global Burden of Disease Study [8]. Additionally,
tuberculosis remains one of the leading causes of morbidity and
mortality in many settings, particularly in the world’s poorest
countries. It is estimated that of the approximately 8.9 million
people that developed tuberculosis in 2004, nearly 1.7 million
people died from it [9].
Studies in animal models of Th1-inducing pathogens and in
pre-clinical trials with certain vaccines showed that infection with
helminthic parasites impaired Th1 immune responses
[10,11,12,13,14]. This decrease in immunogenicity of BCG
(Bacillus Calmete-Gue ´rin, the current vaccine against tuberculosis)
was described in a study conducted in a rural community in
Ethiopia where healthy or helminth-infected volunteers received
anti-helminthic therapy or placebo, and were subsequently
vaccinated with BCG. In that study, the authors showed that
helminth infection impaired IFN-c secretion and increased TGF-b
production by peripheral blood mononuclear cells stimulated in
vitro with PPD (purified protein derivative) after BCG vaccination
[15]. These findings highlight potential explanations for the
apparent failure of BCG to prevent pulmonary tuberculosis in
populations inhabiting tropical regions.
Vaccines against tuberculosis (TB) under development include
attenuated or enhanced live whole-cell, inactivated whole-cell,
www.plosntds.org 1 June 2010 | Volume 4 | Issue 6 | e700subunit, virus-vectored, and DNA vaccines followed by several
immunization strategies using prime-boost protocols. Several of
these candidate vaccines have demonstrated activity in animal
models that is equal or superior to that of BCG; trials in human
subjects are currently under way [16]. We have previously
demonstrated that a DNA vaccine encoding the mycobacterial
65-kDa heat shock protein (DNAhsp65) protected mice and
guinea pigs from challenge with a virulent strain of Mycobacterium
tuberculosis (Mtb) [17,18] and, further, cured previously infected
mice when administered as naked DNA by intramuscular injection
[19]. We have also shown that therapeutic use of DNAhsp65 in
combination with anti-mycobacterial drugs shortens the duration
of TB treatment, improves treatment of latent TB infection, and is
effective against multi-drug resistant TB [20]. However, to
improve therapies and vaccination protocols against tuberculosis
it is important to investigate the influence of helminth coinfection
on the immune response during TB [21] and its effects on
treatment and immunization. We previously showed that infecting
BALB/c mice with the helminth Toxocara canis elicited a Th2
response but did not alter susceptibility to subsequent infection
with M. tuberculosis [22]. In contrast, Schistosoma mansoni infection
can strongly enhance susceptibility to TB [13] and impair the
protective effects of BCG vaccination [23].
Here, we show that the immune and pathological responses
induced by coinfection with T. canis or S. mansoni and TB did not
abrogate the therapeutic effect of the DNAhsp65 vaccine. We
found that the therapeutic effect was maintained due to Hsp65-
specific IFN-c production as well as an inhibition of TGF-b
production in the lung. These results suggest that the DNAhsp65
vaccine may provide an elegant vaccination strategy in tropical
countries where infections with multiple pathogens are common
and lead to altered immune responses.
Materials and Methods
Animals
Specific pathogen-free female 6-week-old BALB/c mice were
obtained from the animal facilities of Faculdade de Cie ˆncias
Farmace ˆuticas - Universidade de Sa ˜o Paulo and bred in a SPF
facility. All experiments were approved and conducted in
accordance with the guidelines of the Animal Care Committee
of the University. Infected animals were housed in cages within a
laminar flow safety enclosure and kept in a Biosafety Level 3
biohazard animal room.
Plasmid construction and purification
DNAhsp65 vaccine was derived from the pVAX1 vector
(Invitrogen, Carlsbad, CA, USA), which had previously been
digested with BamHI and Not I (Invitrogen) and a 3.3-kb fragment
(corresponding to the M. leprae HSP65 gene) was inserted. The
vector pVAX1 was used as control. Plasmids were replicated in
DH5a Escherichia coli and purified with Endofree Plasmid Giga kit
(Qiagen, Valencia, CA, USA) according to the manufacturer’s
protocol. Endotoxin levels were determined using a QCL-1000
Limulus amebocyte lysate kit (Cambrex Company, Walkersville,
MD, USA) and were less than 0.1 endotoxin units (EU)/mg DNA.
Experimental infection
T. canis. T. canis eggs were obtained by the Olson and Schulz
method [24], modified by Faccioli et al. [25]. In brief, pregnant
female worms were recovered from dogs. Then, the eggs were
rescued from the worm uterus, washed and maintained in 0.5%
formalin at 37uC in shallow dishes, where they developed into an
infective stage. Before being used, the eggs were thoroughly washed
with saline. Infective doses of 500 embryonated eggs in 0.5 ml of
saline were prepared. Mice were infected by gastric intubation via a
metal cannula. Control animals received only 0.5 ml of saline.
S. mansoni. S. mansoni LE strain was maintained by routine
passage through Biomphalaria glabrata snails and BALB/c mice.
Infected snails were induced to shed cercariae under light exposure
for 2 h; cercariae were recovered by sedimentation on ice. The
number of cercariae in suspension was determined and mice were
percutaneously infected with 30 cercariae/mouse using a procedure
adapted from the ring method [26].
M. tuberculosis. The H37Rv strain of M. tuberculosis
(American Type Culture Collection, Rockville, MD) was grown
in 7H9 Middlebrook broth (Difco Laboratories, Detroit, MI) for 7
days. The culture was harvested by centrifugation and the cell
pellet was resuspended in sterile phosphate buffered saline (PBS)
and vigorously agitated. The homogeneous suspension was filtered
through a 2-mm filter (Millipore, Bedford, MA). Because CFU
determination takes 4 to 6 weeks, we used fluorescein diacetate
(Sigma, Saint Louis, MO) and ethidium bromide staining [27] to
rapidly assess the viability of M. tuberculosis cultures upon infection.
An anterior midline incision was made to expose the trachea. A
30-gauge needle attached to a tuberculin syringe was inserted into
the trachea and intratracheal dispersion was used to introduce 10
4
CFU (in S. mansoni coinfection experiments) or 10
5 (in T. canis
coinfection experiments) viable CFU of M. tuberculosis H37Rv in
100 ml of PBS into the lungs [28]. Control mice received only
intratracheal PBS.
As shown on the chart in Figure S1, infection with M. tuberculosis
was performed 18 days or 42 days after the Toxocara canis or S.
mansoni infection, respectively. At these two time-points, each
worm induces an optimal Th2 response [29,30] due to the visceral
larva migrans syndrome present in toxocariasis and the incidence
of eggs in the liver and intestine of S. mansoni infected hosts.
DNA vaccination therapy
DNA vaccination was initiated 30 days after TB induction by
injection of 50 mg of plasmid DNA in 50 ml of saline into the
quadriceps muscle of each hind leg, on four occasions at 10-day
Author Summary
From 14 diseases considered by WHO as Neglected
Tropical Diseases, four involve helminth infections, such
as schistosomiasis and soil-transmitted helminthiasis.
Toxocariasis is a soil-transmitted worm highly prevalent
in many developing countries, while schistosomiasis
causes an annual mortality of 14,000 deaths per year, with
200–300 million infected people and 10% at risk of
infection worldwide. Additionally, tuberculosis (TB) re-
mains one of the leading causes of morbidity and mortality
in many settings, particularly in the world’s poorest
countries. Mycobacteria and helminths are co-endemic
and induce opposing patterns of immune responses in the
host, recognized as Th1 and Th2 respectively. These co-
existing patterns could be associated with the failure of TB
vaccines. In this sense, we investigated the inflammatory
and immune response in a coinfection model with T. canis
or S. mansoni and M. tuberculosis analyzing the effects of
an immunotherapy that has previously shown efficacy in
experimental TB. This immunotherapy is based on a DNA
vaccine that codifies a mycobacterial heat shock protein
(hsp65), which can prevent TB in a prophylactic and also
therapeutic setting. In this work, we show that helminth
coinfection does not abrogate the therapeutic effects of
DNAhsp65 vaccine against TB.
DNA Vaccine in TB/Worm Coinfection
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bacterial growth, lung histology, and cytokine production by lung
or spleen cells were accessed (Figure 1). All figures represent the
results from one of three representative experiments: first lungs
were removed, using the right cranial lobe and right middle lobe
for homogenization, the right caudal lobe for fixation and the left
lobe and accessory lobe for CFU. The spleen was also removed
from the same mice.
Determination of M. tuberculosis colony forming units
(CFU) in lungs
Recovery of M. tuberculosis was performed as described
previously [31]. Briefly, the number of live bacteria recovered
from the lungs was determined as CFU by plating 10-fold serial
dilutions of homogenized tissue on Middlebrook 7H11 agar
(Difco) incubated at 37uC. Colonies were counted after 28 days.
Results are expressed as log10 of CFU/g lung.
Measurement of cytokines and nitrite levels in lung
tissues
For cytokine measurements, lungs were removed and homoge-
nized in 2 ml RPMI 1640, centrifuged at 4506g and the
supernatant was stored at 270uC until assayed. Commercially
available enzyme-linked immunosorbent assay (ELISA) antibodies
were used to measure IL-4, IL-5, IL-10, TGF-b, IL-12, and IFN-c
(OptEIA
TM BD-Pharmingen, San Diego, CA). Plates were coated
with 100 ml/well of the capture antibody (1–4 mg/ml) diluted in
Coating Buffer (0.1 M Sodium Carbonate, pH 9.5) and incubated
overnight at 4uC. Plates were washed 5 times with 300 ml/well
Wash Buffer (PBS with 0.05% Tween-20) and non-specific binding
was blocked by addition of 200 ml/well Assay Diluent (PBS with
10% FBS, pH 7.0), and incubated at room temperature for 1 hour.
After washing as above, 100 ml of standards, samples, and controls
were added into appropriate wells and incubated for 2 hours at RT.
The plates were washed as above and 100 ml of Working Detector
[Detection Antibody (0.5–2.0 mg/ml)+SAv-HRP reagent] was
added to each well for 1 hour at room temperature. After 7
additional washes, 100 ml of Substrate Solution (BD Pharmingen
TM
TMB SubstrateReagent Set) was added to each well and incubated
for 30 minutes at room temperature in the dark. The reaction was
stopped by adding 50 ml of Stop Solution (2 N H2SO4) to each well.
Optical density was measured at 450 nm within 30 minutes of
stopping the reaction.
Nitric oxide (NO) production was assessed by measuring nitrite
levels in lung homogenates using the Greiss reagent method [32].
Data are presented as micromoles of NO2
2.
Spleen and lung cell cultures and cytokine determination
Spleens from mice killed 10 days after the last DNA dose were
aseptically removed and minced and the released cells were washed
three times in RPMI 1640 (Gibco BRL, Grand Island, USA).
Minced lungs were next treated with 5 ml/lung of collagenase
solution (0.1 g of Type IV collagenase [Sigma Chemical Co., St.
Louis, USA] in 45 ml of RPMI 1640) and allowed to shake for
30 minutes at 37uC. The suspension was centrifuged at 4506g for
10 minutes and the pellet was suspended in RPMI supplemented
Figure 1. Number of M. tuberculosis colony forming units (CFU) recovered from coinfected mice. Protective efficacy was assessed by
replication of TB bacilli in lungs (A, B) and spleen (C) at the end of DNAhsp65 therapy in animals coinfected with T. canis (A) or S. mansoni (B, C). Data
represent the mean log10 CFU counts 6 SD of five mice per group from one of three independent experiments. *p,0.05 versus Mtb;
#p,0.05 versus
Sm+Mtb or Tc+Mtb;
&p,0.05 versus respective vector group.
doi:10.1371/journal.pntd.0000700.g001
DNA Vaccine in TB/Worm Coinfection
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Gibco BRL), streptomycin (100 mg/ml, Gibco BRL). Cells from
lung or spleen were suspended at 5610
6 cells per ml in
supplemented RPMI and dispensed into 96-well flat-bottom
microtiter plates in a volume of 0.1 ml. A total of 10 mg/ml
recombinant Hsp65 was added to wells (0.1 ml) in triplicate and
maintained for 48 h at 37uC. Commercially available ELISA
antibodies were used to measure IFN-c (OptEIA
TM BD-Pharmin-
gen) in supernatants of cultured cells as above.
Statistical analysis
Data are represented as mean 6 SEM, n=5 (PBS group) or
n=6 (other groups) and were analyzed with using GraphPad
Prism version 4.02 for Windows (GraphPad Software, San Diego,
CA). Comparisons were performed using unpaired t tests for CFU
analyses or one-way ANOVA with Bonferroni’s post test for other
experiments. Differences were considered significant if P,0.05.
Experiments were repeated 2–3 times and similar results were
observed in all experiments.
Results
DNAhsp65 therapy in helminth-TB coinfected mice
causes decrease of M. tuberculosis replication and
sustains a preserved lung architecture
As shown previously [19,28], DNAhsp65-therapy was effective
in reducing the number of CFU in Mtb-infected mice (black bars,
Figure 1A–C), whereas the treatment with empty vector was not.
We have also demonstrated previously that coinfection with T.
canis could not increase susceptibility to TB [22]. Here, we
confirmed this data (Figure 1A), showing that numbers of bacteria
in the lung of T. canis-coinfected mice were quite similar to those in
Mtb-infected mice. On the other hand, S. mansoni-coinfection
resulted in an increase in CFU counts, demonstrating greater
susceptibility to M. tuberculosis bacilli under these conditions,
confirming previously published data [13].
To evaluate whether helminth infection could impair
DNAhsp65-induced protection against M. tuberculosis, mice were
coinfected with worms and treated with DNAhsp65 following the
time line presented in Figure S1. Although T. canis-coinfection did
not change bacterial burden in the lungs, we also observed that
this helminth did not influence the therapeutic effect of DNAhsp65
(Figure 1A), since we observed a similar reduction in CFU in lungs
tissue in both Mtb hsp65 and Tc+Mtb hsp65 groups. Surprisingly,
therapy with DNAhsp65 was also highly effective in S. mansoni-
coinfected animals, as CFUs were reduced in lungs of this group
(Figure 1B). Due to the ability of S. mansoni to alter the immune
response in a concomitant Mtb infection [13], different from T
canis that does not influence in bacteria burden [22], we also
evaluated CFU levels in the spleen after treatment with
DNAhsp65 and found that the differences in CFU counts
suggested that the DNAhsp65-therapeutic effect observed in lungs
is maintained systemically (Figure 1C).
Histological analysis of the lungs also revealed that cellular
accumulation, cellular organization and pulmonary parenchyma
commitment were similar in T. canis coinfected and M. tuberculosis
infected mice. In contrast, S. mansoni coinfection induced greater
lung injury when compared to M. tuberculosis infection itself
resulting in increased inflammatory cells numbers and greater
tissue congestion. Treatment with empty vector did not alter lung
pathology or CFU either in mice infected with M. tuberculosis or
coinfected with helminths. In contrast, DNAhsp65 therapy
resulted in a significant decrease in lesions in the Mtb group and
the coinfected groups. Histological sections of HE-stained lungs
from coinfected and M. tuberculosis infected mice were character-
ized predominantly by the presence of macrophages and
lymphocytes that accumulated mainly in perivascular and
peribronchial areas. Immunotherapy with DNAhsp65 partially
reversed the pathologic effects resulting in a large preserved area
in the lung parenchyma (Data not shown).
The therapeutic effect of DNAhsp65 was maintained
during coinfection due to modulation of immune
response in lungs
As nitric oxide (NO) is an important microbicidal factor, we
analyzed its production indirectly within the lung parenchyma
through measurement of NO2
2. Mtb-infected mice showed
increased levels of NO compared to cells from control animals.
Cells obtained from coinfected animals showed similar NO
production levels when compared to Mtb-infected animals.
DNAhsp65 treatment did not alter these high NO levels in any
group (Figure 2C and F).
Since proinflammatory and Th1 cytokines play important role
in the immune response against M. tuberculosis, we sought to
investigate whether coinfection could alter cytokine production in
lungs after DNAhsp65 treatment. Lung cells were obtained from
animals that were either coinfected or singly Mtb-infected and
treated with or without DNAhsp65. In Mtb-infected animals, IL-
12 and IFN-c levels in the lungs were increased when compared to
mice receiving PBS or infected only with T. canis (Figure 2A and B)
or S. mansoni (Figure 2D and E). These cytokines were present at
similar levels in coinfected and Mtb-infected animals, even after
DNAhsp65 treatment. Besides helminth infection are marked by a
Th2 pattern, during coinfection the Th1 pattern kept elevated as
seen during infection with M. tuberculosis only.
In an attempt to determine those elements of the immune
system that respond to DNAhsp65 immunotherapy, we analyzed
Th2 and regulatory cytokine profiles in lungs following DNAhsp65
treatment. Infection with T. canis induced elevated levels of IL-4,
IL-5, and IL-10 compared to control mice (Figure 3A–C).
However, in T. canis coinfected mice, regardless of DNAhsp65
therapy, the levels of these cytokines were reduced to control
levels. Similar to T. canis infection, S. mansoni caused elevated levels
of IL-4, IL-5, IL-10, and TGF-b when compared to PBS and Mtb
groups (Figure 3D–G). In the S. mansoni coinfection scenario, these
high levels of cytokine expression were maintained. Interestingly,
DNAhsp65 therapy markedly reduced Th2 and regulatory
cytokine levels induced by S. mansoni, suggesting a pathway for
the protection observed in these mice.
DNAhsp65’s therapeutic effect is correlated with in vitro
IFN-c production
A Th1 response is a key element during the immune response
against TB since it is critical in preventing progression to active
disease. The presence of IFN-c at the site of infection can
circumvent the tendency of Mtb to escape phagosome maturation
and facilitate control of bacterial burden [33]. To determine
whether DNA immunization induced specific T cell stimulation,
spleen or lung cells were obtained after coinfection and therapy
and cultured in the presence of recombinant HSP65. The
supernatants were collected after 48 h in cell culture and were
analyzed for IFN-c production by ELISA.
IFN-c expression was significantly upregulated in spleen cells
from infected mice receiving DNAhsp65 therapy (Figure 4A). This
was observed in treated mice infected with Mtb or coinfected with
T. canis. All other conditions produced IFN-c levels that were not
significantly different from control values. Thus, high levels of
DNA Vaccine in TB/Worm Coinfection
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treatment and may account, at least in part, for the observed
positive therapeutic effects.
In the S. mansoni-coinfection model, we analyzed HSP65-specific
IFN-c production by lung cells. As Figure 4B shows, lung cells
obtained after Mtb infection produce more IFN-c when stimulated
in vitro with rHSP65 than lung cells from PBS and Sm groups.
However, treatment with DNAhsp65 could increase these levels
significantly in Mtb-infected and coinfected mice. This elevated
production was not observed in untreated or vector treated mice,
highlighting the specific therapeutic effects of DNA treatment in
Mtb as well in coinfected groups (Figure 4).
Discussion
According to the World Health Organization (WHO),
Neglected Tropical Diseases, as helminth infections, have a
major adverse impact on the health, well-being, and socioeco-
nomic development of poverty-stricken people living in low-
income countries [34,35]. Because mycobacterial and helminth
pathogens are frequently co-endemic and tend to induce
opposing immune responses, we investigated the pattern of
inflammatory and immune responses in coinfection models
featuring pre-exposure to T. canis or S. mansoni and challenge
with M. tuberculosis to assess effects of a therapeutic DNA vaccine
that has shown efficacy in experimental TB. In our study, we
showed that worm coinfection did not abrogate DNAhsp65
therapeutic effects during TB. Coinfected mice had no modula-
tion in Th1 immune response, but present high levels of Th2 and
regulatory cytokines, which was related with lung damage (data
not shown). When DNA therapy was evaluated, we observed
increasing in IFN-c produced by rHsp65 recalled cells (Figure 4)
and downregulation of Th2 and regulatory cytokines in the lungs
of coinfected and treated mice (Figure 3). This immune
modulation culminated in preserved therapeutic properties
attributed to DNAhsp65 in TB/helminth coinfection models.
Figure 2. Th1 cytokine and nitrite levels in lung parenchyma from coinfected mice after treatment. Mice were infected with T. canis (A,
B, C) or S. mansoni (D, E, F) and coinfected with M. tuberculosis. After TB establishment, mice received 4 doses of DNAhsp65 and the lungs were
homogenized. Cytokine levels in supernatant were measured by ELISA and nitrite production was quantified by Griess reaction. *p,0.05 versus PBS.
doi:10.1371/journal.pntd.0000700.g002
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Mycobacterium leprae (hsp65) as a vaccine antigen against several
experimental pathologies including TB [20,28,36], diabetes [37],
arthritis [38], leishmaniasis [39], and cancer in phase I clinical
trials [40,41]. The success of hsp65 vaccination in these different
diseases reflects its effectiveness as an immunodominant antigen
and also suggests that it produces hsp-dependent effects, such as
those ascribed to other heat shock proteins [42]. The search for
new vaccines and therapies against TB is due in part to the widely
variable protective efficacy of BCG which ranges from 0 to 80%
protection depending on the country [43], as well as the fact that
BCG protects against TB in newborns, but does not prevent latent
TB or reactivation in adults [44,45]. One hypothesis regarding the
variability of BCG efficacy in developing countries includes the
presence of Th2-cell and Treg responses, which could be driven by
co-existing helminth infections or environmental mycobacterias
[46]. In 2005, Elias and coworkers showed for the first time that a
helminth infection could alter the in vivo protective effect conferred
by BCG immunization [23]. This pivotal study showed that mice
previously immunized with BCG and co-infected with S. mansoni
were more susceptible to TB, showing increased bacterial load and
lung pathology. Moreover, when spleen cells from these coinfected
mice were stimulated in vitro with PPD (purified protein derivative),
they produced lower IFN-c and nitric oxide levels.
We demonstrated previously that T. canis infection does not lead
to increased susceptibility to pulmonary tuberculosis [22] and in
the present work we show that pre-exposure to T. canis infection
does not affect the therapeutic effects of DNAhsp65. Recently, S
mansoni infection has been reported to increase susceptibility to TB
[13], which was confirmed in the present work using a different
route of TB infection. Mice coinfected with S. mansoni and M.
tuberculosis presented increases in lung inflammation and CFU
counts, accompanied by augmentation of Th2 cytokine release in
lung tissue. In contrast, T. canis coinfection did not increase
susceptibility to TB or alter Th1 cytokines production. These
observed changes in Th1 and Th2 phenotypes may account for
the differences in TB susceptibility between S. mansoni and T. canis
coinfection. Despite this, the DNAhsp65 vaccine proved capable
of maintaining its therapeutic properties even under TB and S.
mansoni coinfection.
As we can observe in the Figure 3, Th2 (IL-4 and IL-5) and
regulatory (IL-10 and TGF-b) cytokines were downregulated in S.
mansoni coinfected mice treated with DNAhsp65 compared to
untreated coinfected mice, correlated to CFU counts. Indeed,
Th2 lymphocyte subsets have been observed in lung tissue from
patients with cavitary tuberculosis, compared with Th1 subsets in
non-cavitary disease, suggesting that IL-4 might be an indicator
of disease severity [47] and that the Th2 environment can
increase immunopathology [48]. These data suggest that the
suppression of Th2 and regulatory cytokines induced by
DNAhsp65 conferred the protection of the lung parenchyma
observed in coinfected hosts. Mutapi and colleagues [49]
suggested that Th1/Th2 dichotomy does not sufficiently explain
susceptibility or resistance to schistosome infection. Hosts who
produce IFN-c/IL-4/IL-5 in association with IL-10 present high
levels of infection, proposing that the regulatory component is
strongest to define the severity of pathology. In our results we
observed lung damage in coinfected hosts (data not shown),
associated with high IFN-c, IL-4/IL-5 and IL-10/TGF-b,b u t
when mice were treated with DNAhsp65 the regulatory and Th2
components were inhibited and Th1 kept elevated, allowing the
preservation of lung integrity. Successful TB control depends on a
finely tuned system where IFN-c provided by effector T cells
confers tuberculostatic and tuberculocidal activities to macro-
phages [50,51]. We suggest that the treatment downmodulated
the regulatory cytokines in the lung and simultaneously increased
the antigen recalled IFN-c production, allowing to the control of
TB in coinfected treated hosts.
Helminth infections can activate and expand the T regulatory
cell population (Treg) in mice as well as in humans. Tregs play an
important role in the suppression of Th1 functions during the
immune response induced by S. mansoni egg antigens and can also
control the Th2 response in chronic infection [52]. Elias and co-
workers recently showed that peripheral blood mononuclear cells
from BCG-immunized, chronically infected S. mansoni patients
showed increased TGF-b production without an enhanced Th2
immune response when stimulated in vitro with PPD, indicating
that this phenomenon was related to reduced immunogenicity of
BCG [15]. Our data suggest that DNAhsp65 treatment inhibited
the soluble factors involved in Treg–mediated immunosuppres-
Figure 3. Th2 and regulatory cytokines levels released by lung cells of coinfected mice after treatment. Mice were coinfected with T.
canis (A, B, C) or with S. mansoni (D, E, F, G) and received 4 doses of DNAhsp65. Ten days after the last vaccine dose, the lungs were homogenized and
cytokine levels in supernatant were measured by ELISA. *p,0.05 versus PBS;
#p,0.05 versus Sm+Mtb or Tc+Mtb.
doi:10.1371/journal.pntd.0000700.g003
Figure 4. In vitro IFN-c production by cells stimulated with
rHSP65. After coinfection and DNAhsp65 therapy, total spleen cells (A)
or lung cells (B) were stimulated in vitro with rHSP65 (black bars) or
were left unstimulated (white bars) for 48 h. Cytokine levels in culture
supernatants were determined by ELISA. *p,0.05 versus PBS;
#p,0.05
versus Mtb;
&p,0.05 versus Sm+Mtb or Tc+Mtb.
doi:10.1371/journal.pntd.0000700.g004
DNA Vaccine in TB/Worm Coinfection
www.plosntds.org 7 June 2010 | Volume 4 | Issue 6 | e700sion, as indicated by the decrease in TGF-b and IL-10 production
observed in treated co-infected mice. Moreover, DNAhsp65
transfection induces macrophages to produce IL-6 (Data not
shown), a cytokine that decreases suppressive effects of Treg cells
and allows the development of effector responses [53]. Therefore,
we have shown that DNAhsp65 therapy circumvents several
difficulties in coinfected hosts, probably modulating cytokines
production that lead to therapeutic efficacy against TB, highlight-
ing its potential to become a valuable tool against TB. In
conclusion, this study reiterates importance of evaluating the status
of hosts during vaccine development, given the high incidence of
TB/helminthes coinfection.
Supporting Information
Figure S1 Experimental protocols of coinfection and therapy.
(A) BALB/c mice were orally infected with T. canis embryonated
eggs and 18 days after infection, mice were coinfected intratra-
cheally with M. tuberculosis. (B) BALB/c mice were infected with S.
mansoni cercariae and 42 days after infection, mice were coinfected
with M. tuberculosis intratracheally. In both protocols, DNA
vaccination was initiated 30 days after TB induction on four
occasions at 10-days intervals. Ten days after the last dose, mice
were killed and bacterial growth, lung histology and cytokine
production by lung or spleen cells were assessed.
Found at: doi:10.1371/journal.pntd.0000700.s001 (0.40 MB TIF)
Alternative Language Abstract S1 Translation of the abstract
into Brazilian Portuguese by author FGF.
Found at: doi:10.1371/journal.pntd.0000700.s002 (0.03 MB
DOC)
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